US 12,303,512 B2
Therapeutically active compounds and their methods of use
Chandra Agarwal Prakash, North Andover, MA (US)
Assigned to Servier Pharmaceuticals LLC, Boston, MA (US)
Filed by Servier Pharmaceuticals LLC, Boston, MA (US)
Filed on Oct. 2, 2023, as Appl. No. 18/479,185.
Application 18/479,185 is a division of application No. 17/668,649, filed on Feb. 10, 2022, granted, now 11,865,079.
Claims priority of provisional application 63/217,843, filed on Jul. 2, 2021.
Claims priority of provisional application 63/149,075, filed on Feb. 12, 2021.
Prior Publication US 2024/0041892 A1, Feb. 8, 2024
Int. Cl. A61K 31/53 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01)
CPC A61K 31/53 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 45/06 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01)] 21 Claims
 
1. A method of treating a cancer comprising administering to a patient in need thereof a therapeutically effective amount of a purified compound or a pharmaceutically acceptable salt thereof, wherein the cancer is characterized by the presence of at least one mutation chosen from an IDH1 mutation or an IDH2 mutation and wherein the purified compound is selected from:

OG Complex Work Unit Chemistry